At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Favipiravir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19
In Brief
A Phase 2 clinical trial evaluating Favipiravir and Standard of Care for COVID-19. Completed, enrolled 50 participants across 8 sites.
Detailed Summary
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedApr 2020
Primary CompletionSep 2020
Study CompletionOct 2020
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartApr 17, 2020
Primary CompletionSep 30, 2020
Study CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.2 years ago
Interventions
Favipiravirdrug
Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
Standard of Careother
Standard of Care for individual study site as determined by each hospital's protocol